Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB)
Yongge Liu(Pharmaceutical Product Development (United States)), Jeffrey Hafkin(Otsuka (United States)), Rajesh Gupta(Pharmaceutical Product Development (United States)), Kinue Ohguro(Otsuka (Japan)), Masuhiro Yoshitake(Pharmaceutical Product Development (United States)), Hidekaza Ishida(Otsuka (Japan)), Makoto Matsumoto(Tottori University Hospital), Lawrence Geiter(Pharmaceutical Product Development (United States))
Cited by 164
Related Papers
A Toll-like receptor recognizes bacterial DNA
|Nature|2000|6.4k
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
|The Lancet|1986|2.4k
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
|Immunity|1998|2k
Essential role of Stat6 in IL-4 signalling
|Nature|1996|1.6k
Targeted disruption of the mouse <i>Stat3</i> gene leads to early embryonic lethality
|Proceedings of the National Academy of Sciences|1997|1.3k